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Abstract 
Purpose: To investigate whether or not fibroblast growth factor (FGF-21) can be used as a screening 
biomarker in chronic progressive external ophthalmoplesia (CPEO) patients. 
Methods: FGF-21 concentration was measured in the serum of 24 patients with CEPO phenotype and 
24 control samples by enzyme-linked immunosorbent assay (ELISA) and determined the deletion of 
mitochondrial genome by multiplex polymerase chain reaction (PCR). 
Results: FGF-21 concentration in 50 % of CPEO patients showed notable differences from that in 
control subjects. FGF-21 concentration ratio in patient group, 2 disorder control groups (mitochondrial 
and non-mitochondrial) and normal group, respectively, was 294.87 ± 42.10 (p < 0.0001), 761.78± 
75.07 (p < 0.0001), 124.26 ± 12.27 (p = 0.1203), 69.27 ± 10.09 (p = 0.2195). A statistically significant 
inverse correlation between FGF-21 concentration and age onset was found, with a significant 
difference (p < 0.05) in the age group ≤ 19 years (mean FGF-21 concentration, 460.36 pg/mL) and for 
the age group  ≥ 51years (mean concentration FGF-21, 57.87 pg/mL. Surprisingly, there was no 
significant difference between FGF-21 concentration and age in the mid-age group (20 – 50 years) .  
Conclusion: These findings indicate that FGF-21 concentration significantly increases in CPEO 
patients like in other mitochondrial disorders and this factor can be used as a biomarker in primary 
diagnosis of mitochondrial disorders. In this regard, FGF-21 assay is only valid in teenagers and the > 
50 years age group who show acute symptoms. 
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INTRODUCTION 
 
Mitochondrial diseases include a group of 
metabolic disorders that affect people of all ages 
[1]. Based on subsarcolemmal accumulations of 
abnormal mitochondria and their intense red 
appearance with histological staining, 
mitochondrial diseases are divided in two major 
groups; ragged-red fiber disorders and non-
ragged-red fibers ones. The first group includes 
diseases such as Kearns-Sayre syndrome 
(KSS), mitochondrial encephalopathy with lactic 
acidosis and stroke-like episodes (MELAS), 
myoclonic epilepsy with ragged red fibers 
(MERRF), Pearson syndrome, progressive 
external ophthalmoplegia (PEO) [2,3].  
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CPEO is a mitochondrial myopathy that causes 
muscular or multisystem symptoms [4]. The 
disease is characterized by a progressive 
involvement of the ocular musculature, with 
ptosis of the eyelids and impairment of eye 
movements [4,5]. Lactate, pyruvate, aminoacids 
and creatine kinase are considered as serum 
markers for the diagnosis of mitochondrial 
disorders. However, since they do not have a 
good sensitivity and specificity for such a 
detection muscle biopsy is considered as a better 
tool for detecting extensive intra-muscular 
mitochondrial damages [6-8]. On the other hand, 
biopsy is an invasive procedure that is more 
costly than testing a serum biomarker; 
furthermore, children would require a general 
anesthesia in biopsy.  
 
Suomalainen et al introduced fibroblast growth 
factor 21 (FGF-21) as a new serum biomarker in 
patients with mitochondrial dysfunctions [7].  
Consequently, the aim of this study was to 
determine if the measurement of FGF-21 
concentration in the serum of Iranian patients 
with CPEO can be used as a biomarker for 
human mitochondrial disorder. 
 
EXPERIMENTAL 
 
Patients 
 
24 patients (14 men and 10 women) with CPEO 
were referred to the Genetics Department at 
Special Medical Centre (SMC) of Tehran for 
diagnosis. Documented, written consent was 
obtained from all patients who agreed to 
participate. The study protocol was approved by 
SMC project Nr 385 ethics committee according 
to World Medical Association's Declaration of 
Helsinki [9]. Our study was performed according 
to WHO criteria [10].  Serum samples were 
collected from CPEO patients and control 
groups, comprised of two groups of non-
mitochondrial (control group 1)  and other 
mitochondrial disorders except CPEO (control 
group 2), e.g., mitochondrial myopathy, Leber’s 
hereditary optic neuropathy (LHON), 
mitochondrial encephalomyopathy, lactic 
acidosis, and stroke (MELAS); control group 2 
consisted of 9 mitochondrial and 5 non-
mitochondrial disorder patients,while the healthy 
control group comprised of 5 men and 5 women. 
These cases are listed in Table 1 and Table 2. 
 
FGF-21 concentration measurement 
 
ELISA (BioVendor Human FGF-21 ELISA Kit) 
was used to measure FGF-21 concentration in 
serum samples. For FGF-21, the cutoff was 
based on the reference ranges stated in the 
study of the Suomalainen et al. [7]. Thus, the 
cutoff value used ws 200 pg/mL. 
 
Molecular study 
 
Due to the fact that in most cases, CPEO occurs 
as result of a sporadic deletion of mitochondrial 
genome, multiplex polymerase chain reaction 
(PCR) was used to study mtDNA in patients who 
showed symptoms of the disease. Six primers 
were used to analyze the whole mitochondrial 
genome. 
 
A pair of primers related to the mtDNA region 
that is generally not deleted was used as internal 
control, and the others were used to show delete 
regions. The PCR of each sample was set in a 
0.2 ml tube using 100 mg of total DNA, 10 pmol 
of each primer, 200 mmol of dNTPs, 1X PCR 
buffer containing 2.5 mmol MgCl2 and 1 U Taq 
DNA polymerase (Roche Diagnostics, 
Mannheim, Germany). The cycling conditions 
used for the amplification were as follows: initial 
denaturation at 94 °C for 5 min followed by 35 
cycles of denaturation for 1 min at 94 °C, 
annealing for 1 min at 55 °C and extension for 35 
sec at 72 °C (final extension for 10 min). 
 
Statistical analysis 
 
P < 0.05 was considered statistically significant 
and this was assessed using Duncan’s multiple 
range test to compare FGF-21 concentrations 
between patients and controls. Also compared 
were FGF-21 concentrations between the 3 age 
groups (≤ 19 years 20 - 50 years and ≥ 51 years) 
in CPEO patients. Data are expressed as mean 
± standard error (SE). 
 
RESULTS 
 
The concentration of FGF-21 in 50 % of cases 
(total: 48) with CPEO phenotype was not in the 
normal range. While there was no increase in 
FGF-21 concentration in healthy and non-
mitochondrial disorder control groups, a higher 
concentration was detected in the mitochondrial 
disorder groups (CPEO and other mitochondrial 
disorders). The outcomes of statistical 
comparisons of the pertinent parameters are 
shown in Tables 3 and 4.   
 
Genetic analysis showed that 50 % of patients 
with CPEO clinical symptoms as well as 
increased serum FGF-21 concentration, there 
was deletion of mtDNA, while in the other 
patients with CPEO clinical symptoms and 
normal serum FGF-21 concentration, there was 
no deletion of mtDNA. The observed bands on  
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Table 2: Serum FGF-21 concentrations in 3 control groups; disease control group (non-mitochondrial: mental 
retardation, epilepsy, dismorphia, DMD and other mitochondrial disorders: LHON, MELAS, mitochondrial 
myopathy) and healthy control group. 
 
Case no. Sex Age (years) Clinical feature FGF-21(pg/ml) 
1 F 44 LHON 789.8 
2 F 52 LHON 1549 
3 M 17 LHON 451.6 
4 M 22 LHON 824.0 
5 F 20 MELAS 723.1 
6 M 51 MELAS 612.8 
7 M 55 Mitochondrial myopathy 619.0 
8 F 27 Mitochondrial myopathy 830.0 
9 F 36 Mitochondrial myopathy 456.8 
10 F 28 Mental retardation 62.4 
11 F 18 Epilepsy 169.1 
12 F 22 Epilepsy 151.3 
13 M 38 Dismorphia 128.2 
14 M 29 DMD 110.3 
15 F 15 Healthy 48.2 
16 F 43 Healthy 72.7 
17 F 23 Healthy 24.4 
18 M 45 Healthy 16.7 
19 F 56 Healthy 112.5 
20 M 47 Healthy 177.0 
21 M 52 Healthy 56.7 
22 F 32 Healthy 48.3 
23 M 26 Healthy 72.9 
24 M 34 Healthy 63.3 
 
Table 3: Statistical comparison of FGF-21 factor between 4 groups; (group 1: CPEO patients; group 2: other 
mitochondrial disorders; group 3: non-mitochondrial disorders; and group 4: healthy control group) 
 
Group Minimum concentration Maximum concentration Mean ± SE Duncan grouping P-value 
1 8.20 849.80 294.87± 42.10 B <.0001 
2 451.60 1549.00 761.78± 75.07 A <.0001 
3 62.40 169.10 124.26±12.27 C 0.1203 
4 16.70 177.00 69.27±10.09 C 0.2195 
 
 
Table 4: Statistical comparison of FGF-21 factor between 3 age groups; (group 1: ≤ 19 years old; group 2: 20 - 
50 years old; and group 3: ≥ 51 years old). 
 
Group Frequency % Minimum 
concentration 
Maximum 
concentration 
Mean ± SE Duncan 
grouping 
P-value 
1 6 25.00 90.40 849.80 460.36±115.14 A 0.0005 
2 14 58.33 8.20 836.40 291.66±81.58 A,B 0.0007 
3 4 16.67 42.50 88.80 57.87±10.49 B 0.6802 
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Figure 1: Multiplex PCR using ONP 86, ONP 89 and ONP 10 primers. a = left to right; 5 first are related to CPEO 
patients without increase in FGF-21 concentration and the other is related to normal individuals. They show only 
the internal control band in size of 279bp; B = The bands are related to CPEO patients with increase in FGF-21 
concentration. They all show 2 bands, 279bp band is related to ONP 86 and ONP 89 primers as a internal control 
and the upper band is related to ONP 66 and ONP 10 primers that polymerase the DNA when the deletion was 
occurred. The size of this band is 870 bp. 
 
agarose gel electrophoresis showed the 
existence of deletion in the region between two 
primers (Figure 1). The size of the deleted region 
in the CPEO patients with increase in FGF-21 
concentration was 870bp. 
 
DISCUSSION 
 
Mitochondrial disorders are those types of 
metabolic diseases that lead to decrease of 
energy in damaged organs due to defect in 
respiratory chain complexes. However, brain, 
kidney, liver and muscles are the organs that use 
most of the body energy and so are more prone 
to damage [11]. According to the justification of 
Suomalainen et.al [7], FGF-21 is the factor that 
plays an important role in lipid metabolism and 
also FGF-21 concentration increases in 
individuals with mitochondrial disease such as 
MELAS, mitochondrial recessive ataxia 
syndrome (MIRAS), mitochondrial neurogastro-
intestinal encephalopathy (MNGIE); the authors 
proposed this factor as a serum biomarker for the 
diagnosis of mitochondrial disorders [7,12], due 
to the diffulty in carrying out eyelid muscular 
biopsy in CPEO patients with ophtalmoplasia 
phenotype. This is why the concentration of FGF-
21 as a biomarker in this type of mitochondrial 
diseases was undertaken in this study. 
The results obtained in this study show that FGF-
21 could become a suitable general biomarker 
for the diagnosis of mitochondrial diseases. 
These findings reveal that FGF-21 concentration 
will significantly increase in CPEO patients like 
other mitochondrial disorders and hence this 
factor can serve as a biomarker in the primary 
diagnosis of mitochondrial disorders. We also 
suggest 200 pg/mL as a cutoff concentration.  
 
Increased concentration of the test factor in 50 % 
of cases with confirmed CPEO phenotype was 
observed and that it was not gender-dependent; 
however, with regard to age groups, significant 
differences were observed except for the 20 – 50 
years age group.  
 
Although genetic studies on the patients who 
showed increased FGF-21 concentration 
demonstrated partial deletion of mtDNA, similar 
deletion in the other 50 % of patients who 
exhibited normal FGF-21 concentration This 
finding could suggest another genetic factor 
other than mtDNA deletion in the phenotype of 
ophtalmoplasic patients, or misdiagnosis of the 
patients. It must be mentioned that Suomalainen 
et.al’s study was on patients who definitely suffer 
from mitochondrial disorders. In the present, we 
had no access to histological data on the eyelids 
and definite biochemical markers such as COX1 
a 
b 
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for diagnosis of mitochondrial disorders in Iran. 
Nonetheless, this study suggests the possibility 
of the application of FGF-21 assay for diagnosis 
of patients who definitely suffer from 
mitochondrial disorders. 
 
CONCLUSION 
 
It is postulated that FGF-21 factor could serve as 
a serum biomarker for the early diagnosis of 
CPEO in patients with definite mtDNA deletion. 
The low population rate of this phenotype in Iran 
would limit a definitive statement on the 
relationship between the genotype of this 
disease (deletion or non-deletion of mtDNA) and 
increased FGF-21 concentration. However, our 
findings indicate that the application of serum 
FGF-21 concentration not only eliminates the 
need for muscular biopsy but also can be used 
as a predictive test for those CPEO patients who 
have deletion in mtDNA but could not be 
distinguished from other similar clinical 
phenotypes (phenocopies). 
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